Abstract
Background The emergence of new virus variants, including the Omicron variant (B.1.1.529) of SARS-CoV-2, can lead to immune escape and reduced vaccine effectiveness. Neutralizing antibody titers could be used to quickly estimate vaccine effectiveness (VE), because they can be easily measured following the emergence of a new virus variant and have been shown to be a correlate of protection for SARS-CoV-2 and other pathogens. However, few studies have examined VE-neutralizing antibody titer relationships with multiple virus variants, and none have validated relationships for immune evasive variants.
Methods We leveraged variation among vaccines and virus variants to estimate VE-neutralizing antibody titer relationships across a 54-fold range of neutralizing antibody titers for two endpoints for COVID-19: symptomatic disease, and hospitalization. We predicted VEs for Omicron three days after the first neutralizing antibody titer became available. We tested these predictions using subsequently collected observational VE data.
Findings For two mRNA vaccines (mRNA-1273, BNT162b2), fitted models predicted that infection with the BA.1 Omicron variant would increase the risk of hospitalization 2.8-4.4-fold and increase the risk of symptomatic disease 1.7-4.2-fold compared to the Delta variant. However, a third vaccine dose was predicted to restore protection. Out-of-sample validation data indicated that model predictions were quite accurate, with all predictions being within 10% of observed VE estimates, and all empirical estimates fell within the model prediction intervals.
Interpretation These analyses demonstrate that models using neutralizing antibody titers can provide rapid VE estimates which can inform vaccine design and selection.
Funding California Department of Health, National Science Foundation
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
California Department of Health, National Science Foundation
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data used in this ms are freely available
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We have added data to validate the model in the previous version and revised the analytical approach.
Data Availability
All data produced in the present work are contained in the manuscript
